Torrent Pharma Q2 Results: 200-DMA Support in Focus

Torrent Pharmaceuticals is set to announce its Q2 FY27 results today. Market expectations are positive, with analysts focusing on strong domestic growth, improving margins and cost synergies from the JB Pharma acquisition. Nomura estimates EBITDA margins of 34.4%, while US revenue may decline sequentially. Technical View On the daily chart, Torrent Pharma is trading near ₹4,615 after a sharp correction. Price is testing support around the 200-day SMA near ₹4,491, where buyers may attempt a recovery. A potential bullish engulfing pattern near the higher-low zone suggests buying interest, but confirmation is still needed. The stock remains below its 10, 20, 50 and 100-day moving averages. RSI near 40 and a negative MACD indicate that short-term momentum remains weak. Q2 Numbers to Watch - Domestic business growth and JB Pharma integration. - EBITDA margin expansion and cost synergies. - US revenue trends and Brazil business recovery. - Management commentary on future growth and profitability. Key Technical Levels Support: ₹4,490–₹4,500 Resistance: ₹4,620–₹4,695 Major hurdle: ₹4,780–₹4,790 My View Holding the 200-day SMA and moving above ₹4,695 could strengthen the rebound setup. A sustained breakout above ₹4,790 may improve the broader technical outlook. However, a breakdown below ₹4,490 could invite further weakness. Earnings surprises may trigger sharp volatility, so the bullish engulfing pattern needs confirmation. Disclosure: The analyst and their family do not have any position in the stock at the time of writing. This article is for educational purposes only and is not investment advice.